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Abstract
Hepatitis B virus encoded X antigen (HBx) is a trans-regulatory protein that alters the activity of selected transcription factors
and cytoplasmic signal transduction pathways. HBx transcriptionally up-regulates the expression of a unique gene, URG11,
which in turn transcriptionally up-regulates b-catenin, thereby contributing importantly to hepatocarcinogenesis. HBx and
URG11 also alter the expression of multiple microRNAs, and by miRNA array analysis, both were shown to promote the
expression of miR-148a. Elevated miR-148a was also seen in HBx positive liver samples from infected patients. To study the
function of miR-148a, anti-148a was introduced into HepG2 and Hep3B cells stably expressing HBx or stably over-expressing
URG11. Anti-miR-148a suppressed cell proliferation, cell cycle progression, cell migration, anchorage independent growth in
soft agar and subcutaneous tumor formation in SCID mice. Introduction of anti-miR-148a increased PTEN protein and mRNA
expression, suggesting that PTEN was targeted by miR-148a. Anti-miR-148a failed to suppress PTEN expression when co-
transfected with reporter gene mutants in the 39UTR of PTEN mRNA. Introduction of anti-miR-148a also resulted in
depressed Akt signaling by HBx and URG11, resulting in decreased expression of b-catenin. Thus, miR-148a may play
a central role in HBx/URG11 mediated HCC, and may be an early diagnostic marker and/or therapeutic target associated
with this tumor type.
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Introduction
Chronic hepatitis B virus (HBV) infection is associated with the
development of hepatitis, cirrhosis and hepatocellular carcinoma
(HCC). HCC is among the five most frequent cancers worldwide
[1,2]. These diseases have few effective treatments [3]. HBV
makes a genetic contribution to HCC by expressing the HBV-
encoded X antigen, or HBx [4]. HBx is a trans-activating protein
[5] that contributes to the development of HCC by stimulating
cytoplasmic signal transduction pathways [6–12] and by acting as
a transcriptional co-regulatory protein in the nucleus [13–16].
One HBx up-regulated gene, URG11 [17], appears to stimulate
hepatocellular growth by transcriptionally activating the b-catenin
promoter [18]. This may be a part of the mechanism whereby
HBx contributes to HCC [18].
MicroRNAs (miRNAs) are small non-coding RNAs in eukar-
yotic organisms [19] that play key regulatory roles in mRNA
translation and degradation by base pairing to complementary
sites in the 39 un-translated region (39UTR) of selected transcripts
[20]. miRNAs can act as oncogenes or tumor suppressors in
carcinogenesis [21]. Aberrant miRNA expression is associated
with the pathogenesis of many tumor types, including HCC [21–
24]. For example, cyclin G1, which is a target of miR122a, is
down-regulated in HCC [25]. In this context, it is not known
whether HBx or URG11 regulate the expression of miRNAs in
hepatocarcinogenesis. When this was explored by miRNA array,
several miRNAs were deregulated. Among them, miR-148a was
up-regulated by HBx and URG11. Inhibition of up-regulated
miR-148a partially blocked the ability of HBx and URG11 to
promote tumorigenesis. Further work showed that miR-148a
targeted inactivation of the tumor suppressor, phosphatase and
tensin homolog (PTEN), which in turn, modulated b-catenin/Wnt
signaling. Thus, the ability of HBx and URG11 to stimulate
hepatocellular growth via up-regulated expression of b-catenin is
modulated by miR-148a, which in turn, is associated with
a decrease in PTEN activity.
Results
miRNAs Differentially Expressed by HBx or URG11
HepG2, derived from a human hepatoblastoma (a benign
tumor), expresses both wild-type and an activated mutant of b-
catenin [26]. Incontrast, Hep3B, derived from a human hepatoma,
encodes only wild-type b-catenin. Hep3B expressing CAT, HBx or
over-expressing URG11, were previously used to evaluate b-
catenin protein level [18]. Small RNAs isolated from HepG2X and
HepG2CAT cultures were subjected to miRNA array analysis. The
results showed that 46 miRNAs were differentially expressed (P ,
0.01). When the same analysis was applied to HepG2URG11 and
HepG2CAT cells, 55 miRNAs were differentially expressed (P ,
0.01) (data not shown). Three miRNAs were up-regulated and five
miRNAs were down-regulated in both arrays (Table 1). In this
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and 6.49-fold in HepG2URG11 compared to HepG2CAT cells,
was chosen for further characterization.
Confirmation of Up-regulated miR-148a Expression
miR-148a expression was quantified in HepG2X, Hep-
G2URG11 and HepG2CAT cells by using SYBR green qRT-
PCR. miR-148a was up-regulated 1.59 6 0.12-fold in HepG2X
cells and 2.73 6 0.46-fold in HepG2URG11 cells compared to
HepG2CAT cells (Figure 1A). miR-148a was also up-regulated
1.68 6 0.11-fold in Hep3BX and by 2.33 6 0.21-fold in
Hep3BURG11 cells compared to Hep3BCAT cells (Figure 1A).
Hence, miR-148a was up-regulated in the presence of HBx or
over-expressed URG11 in two different liver cell lines.
Dependence of Elevated miR-148a Upon URG11
To confirm that elevated miR-148a was associated with over-
expressed URG11, HepG2 and Hep3B cells expressing HBx or
over-expressing URG11 were transiently transfected with
siURG11. The results showed that miR-148a levels were
depressed by 1.54 6 0.24-fold in HepG2X cells and depressed
by 1.85 6 0.19-fold in Hep3BX cells (Figure 1B). Parallel
experiments using anti-miR-148a for transient transfection (as
a positive control) showed that miR-148a levels were down-
regulated by 1.92 6 0.22-fold in HepG2X cells and by 1.71 6
0.21-fold in Hep3BX cells (Figure 1B). Use of a control siRNA (as
a negative control) yielded 0.16 6 0.02-fold and 0.18 6 0.018-fold
lower levels of miR-148a in HepG2X and Hep3BX cells,
respectively (Figure 1B). These results show that up-regulated
expression of miR-148a in HBx positive cells is URG11
dependent. This was confirmed in parallel experiments with
HepG2URG11 and Hep3BURG11 over-expressing cells
(Figure 1C). Control experiments showed that siURG11 sup-
pressed the expression of URG11, demonstrating that this small
inhibitory RNA was active (Figure 1D).
miR-148a Expression in Clinical Specimens
To determine whether HBxAg expression correlated with
elevated miR-148a in vivo, the expression of HBx and miR-148a
was compared in the tumor (T) and nontumor (NT) compartments
in 19 patients. HBx staining was strong (intensity 2 or 3) in
hepatocytes among 11 of 19 (58%) patients, with mostly lobular or
diffuse tissue distribution (Table 2). In contrast, HBx staining was
detected in the tumor from only 6 patients (32%), and staining was
mostly in scattered cells. Staining was cytoplasmic in both T and
NT cells. HBx staining was dominant in NT compared to T in
each patient, as shown earlier [4]. Similar staining results were
obtained for URG11 (data not shown), as previously published
[18]. Additional characteristics of these patients are presented in
Table 2.
Total small RNA was extracted separately from T and NT
tissues from these same patients. The expression of miR-148a was
then determined by SYBR Green qRT-PCR. The DDCt values
showed that miR-148a was elevated in 13 out of the 19 NT
samples (68%) and in 6 out of 19 tumors (31%) (Table 2). This
corresponds to an average of 14-fold change in miR-148a levels in
NT in 13 patients and an average of 5-fold change in T from the
remaining 6 patients (Table 2). HBx expression in NT was
associated with chronic hepatitis (P , 0.02), cirrhosis (P , 0.01)
and elevated levels of miR-148a (P , 0.001) compared to
uninfected liver. Thus, HBx is associated with up-regulated
expression of miR-148a in NT compared to T by an average of
(14 45) 2.8-fold. This is similar to results seen with HepG2X and
HepG2URG11 compared to control cells. Thus, elevated miR-
148a expression appears to be an early event in the pathogenesis of
HCC, since it was observed most often in infected liver tissues
from which tumor nodules developed. Further, elevated miR-148a
in NT was associated with Edmond III-IV stage tumor (P , 0.001)
and venous invasion (P , 0.001) but not with a tumor capsule (P
. 0.25). These observations suggest that elevated miR-148a
triggered changes in host gene expression that resulted in the
appearance of more aggressive tumors despite the fact that miR-
148a expression was not elevated in most tumors (Figure 2,
Table 2).
Anti-miR-148a Inhibits Cell Growth and Viability
To test whether HBx and URG11 stimulated cell growth is at
least partially dependent upon miR-148a, HepG2X and Hep-
G2URG11 cells were transiently transfected with anti-miR-148a.
The results showed that anti-miR-148a significantly inhibited cell
growth on all days post-transfection, and by day 3, inhibition was
60–70% (Figure 3A). Neither control miRNA introduced into
HepG2X or HepG2URG11 cells, nor introduction of anti-miR-
148a into HepG2CAT cells, inhibited growth at any point in time.
However, significant growth inhibition was observed in Hep3BX
and Hep3BURG11 compared to Hep3BCAT cells (data not
shown). Transfection efficiency was monitored with a Cy5-labled-
miRNA under the same experimental conditions and was
estimated to be close to 100% (data not shown). These
observations suggest that HBx and URG11 promote cell growth,
in part, by up-regulated expression of miR-148a.
To confirm and extend the functional characterization of miR-
148a, HepG2 and Hep3B cells encoding HBx, URG11 or CAT
were stably transduced with recombinant lentivirus encoding anti-
miR-148a. Growth of HepG2X cells stably expressing anti-miR-
148a was inhibited by an average of 68% by day 3 (P , 0.01). For
HepG2URG11, anti-miR-148a inhibited growth an average of
69% by day 3 (P , 0.01) (Figure 3B). Similar inhibition was
observed in Hep3BX and Hep3BURG11 cells stably expressing
anti-miR-148a compared to control miRNA (data not shown).
Growth of HepG2CAT cells was not altered by anti-miR-148a.
These findings again suggest that HBx and URG11 stimulate cell
growth, at least in part, in a miR-148a dependent manner.
To see if elevated miR-148a also promotes cell cycle pro-
gression, Hep3BCAT, Hep3BX, Hep3BURG11 stably expressing
anti-miR-148a or control anti-miR were synchronized by serum
Table 1. Differentially expressed miRNAs in HepG2X and
HepG2URG11 compared to HepG2CAT cells by miRNA array.
Designation Up-regulated
Down-
regulated fold-change
a
HepG2X HepG2URG1
miR-148a + 1.64 6.49
miR-146a + 1.44 2.52
miR-21 + 1.20 1.36
miR-92b + 1.52 1.26
miR-215 + 1.30 4.33
miR-20b + 1.32 3.36
miR-27b + 1.16 1.55
miR-23a + 1.11 4.46
afold-changes for each miRNA in HepG2X and HepG2URG11 cells were
calculated relative to the corresponding miRNA levels in HepG2CAT cells.
doi:10.1371/journal.pone.0035331.t001
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flow cytometry. Day 3 results show that anti-miR-148a suppressed
cell cycle progression into S phase in Hep3BX (P , 0.005)
(Figure 3C). Similar results were seen in Hep3BURG11 (P ,
0.01), and to a lesser extent in Hep3BCAT cells (P , 0.05). The
same trends were observed in these cells at the G2/M transition,
suggesting that miR-148a promotes cell cycle progression,
especially in URG11 over-expressing and HBx expressing cells.
Anti-miR-148a Inhibits Cell Migration
Increased cell migration is another characteristic of tumor cells.
Thus, migration of HepG2CAT, HepG2X and HepG2URG11
cells were evaluated with or without anti-miR-148a. The results
showed that anti-miR-148a, but not control anti-miR, partially
blocked the ability of HBx and URG11 to promote migration of
HepG2 cells after 72 hr (P , 0.01) (Figure 4A). In this case,
HepG2CAT cell migration was also modestly inhibited (P , 0.05),
suggesting that miR-148a promotes cell migration to a greater
extent in HBx or over-expressed URG11 cells compared to
control.
Anti-miR-148a Blocks Colony Formation in Soft Agar and
Tumor Formation in SCID Mice
Prior work showed that HBx and URG11 promoted growth in
soft agar and tumor formation in nude mice [17]. To test whether
miR-148a contributed to tumorigenesis, HepG2CAT, HepG2X,
HepG2URG11 cells stably expressing anti-miR-148a or control
anti-miR were evaluated for anchorage independent growth in soft
agar. Anti-miR-148a suppressed colony formation of HepG2X
cells by an average of 11.8-fold, and that of HepG2URG11 cells
by an average of 2.7-fold, compared to control anti-miR
(Figure 4B, P , 0.01). In contrast, anti-miR-148a did not suppress
HepG2CAT cell growth in soft agar compared to control miRNA
treatment.
The impact of miR-148a upon tumorigenicity was then assessed
by xenotransplantation. For HepG2X and HepG2URG11 cells
expressing anti-miR-148a, tumor growth was partially inhibited
(Table 3), suggesting that up-regulated miR-148a contributes to
HBx and URG11 mediated tumor growth. In contrast, inhibition
of miR-148a in HepG2CAT cells had little impact upon
tumorigenicity. These observations suggest that miR-148a, at
least in part, drives tumor growth mediated by HBx, and in
particular, by over-expression of URG11.
miR-148a Targets PTEN
Putative human gene targets of miR-148a were identified by
using miRanda, TargetScan, and PicTar algorithms. One of the
target genes is the tumor suppressor, PTEN. PTEN expression is
down-regulated by HBx [27]. The homology between miR-148a
and PTEN from miRanda is shown in Figure 5A. In HepG2CAT,
HepG2X, HepG2URG11 cells transiently transfected with anti-
miR-148a, PTEN mRNA levels increased 1.19 6 0.22-fold in
HepG2CAT cells, 1.25 6 0.17-fold in HepG2X cells and 1.34 6
0.20-fold in HepG2URG11 cells compared to cells transiently
transfected with control anti-miR. At the protein level, total PTEN
increased 1.5 6 0.15-fold in HepG2X and 1.72 6 0.18-fold in
HepG2URG11 cells compared to 1.1 6 0.1-fold in HepG2CAT
Figure 1. Relationship between HBx, URG11 and miR-148a expression levels. (A) Endogenous levels of miR-148a were determined in the
indicated cell lines, and their levels normalized to miR-148a in CAT expressing cells. (B) Cells were transiently transfected with URG11 siRNA (white
bars), anti-miR-148a (light gray bars, positive control) or control miRNA (dark gray bars), and the levels of endogenous miR-148a determined. (C)
Parallel experiments as in panel A except that HepG2RG11 and Hep3BURG11 cells were used. (D) Relative levels of URG11 protein in cells transiently
transfected with URG11 specific siRNA or control siRNA. The results show one of three experiments.
doi:10.1371/journal.pone.0035331.g001
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148a target site in the 39UTR of PTEN mRNA was responsible
for its regulation, the 39UTR target site downstream from
a luciferase reporter gene (pEZX-PTEN-39UTR) was co-trans-
fected with either anti-miR-148a or anti-miR control. HepG2X
cells transiently transfected with anti-miR-148a had significantly
higher luciferase activity (2.66-fold, P , 0.02), and so did
HepG2URG11 cells (2.75-fold, P , 0.01), compared to cells
treated with control anti-miR (1.27-fold) (Figure 5C). Given that
the PTEN 39UTR contains two miR-148a binding sites, the wild
type pEZX-PTEN-39UTR was mutated at each or both of these
sites (Table S1). Parallel experiments using reporter plasmids
containing these mutations resulted in little increase in luciferase
activity, suggesting that the mutant PTEN 39UTRs did not bind to
miR-148a (Figure 5C). Taken together, these data suggest that the
binding of miR-148a to the 39UTR of PTEN is specific, and that
PTEN is a target of miR-148a.
miR-148a and Akt Signaling
Since PTEN blocks PI3K activity, experiments were designed
to test whether anti-miR-148a blocks Akt signaling by activating
PTEN and thereby suppressing b-catenin expression. To test this
hypothesis, total and active b-catenin, phosphorylated-GSK3b (p-
GSK3b, Ser9), as well as total and phosphorylated-Akt (p-Akt,
Ser473) levels, were determined in Hep3BX and Hep3BURG11
cells stably expressing anti-miR-148a. Stably expressed anti-miR-
148a was associated with essentially stable levels of total Akt but
significantly decreased levels of activated Akt (p-Akt; P , 0.005).
Likewise, total levels of b-catenin were minimally altered by stable
expression of anti-miR-148a, while the levels of active b-catenin
were depressed in Hep3BX cells (P , 0.05), and in Hep3-
BURG11 cells (P , 0.01), compared to controls (Figure 6).
Further, the inactive form of GSK3b, p-GSK3b, was depressed by
treatment with anti-miR-148a (P , 0.05). These results suggest
that anti-miR-148a inhibits Akt signaling, which results in lower
levels of active b-catenin. qRT-PCR analysis of Akt, GSK3b, and
b-catenin mRNAs showed no differences in cells treated with anti-
miR-148a or control anti-miR (data not shown). Thus, up-
regulated miR-148a, through PTEN, may impact upon Akt
signaling post-translationally.
Relationship between URG11 and PTEN
Since over-expression of URG11 directly correlates with up-
regulated expression of miR-148a (Figure 6), and miR-148a
depresses PTEN protein expression (Figure 5), URG11 may
activate b-catenin by suppressing PTEN. The latter would result in
the activation of PI3K/Akt signaling [28,29]. To test this,
siURG11 was transiently transfected into HepG2CAT, HepG2X,
Table 2. Characteristics of HBxAg and miR-148a in tumor and nontumor compartments from HBV-infected HCC patients.
case No. sex
a age HBsAg (serum)
b HBxAg intensity
d tissue distribution
e
qRT-PCR results for miR-148a
NT
c T
c NT
c T
c DDCt
f fold-change
g
32 1 45 1 1 0 S 21.14 2.20
39 1 44 1 2 0 L,D 21.24 2.36
43 1 53 1 1 0 S +0.63 1.55
86 1 38 1 2 1 L S +2.80 6.96
87 1 71 1 2 1 L S 24.22 18.64
88 1 52 1 2 1,2 D S,L 21.83 3.56
89 1 35 1 1 1.2 S L +0.1 1.07
91 1 66 0 1 0 L 20.7 1.62
95 2 33 1 1,2 1 L S +3.11 8.63
98 1 49 1 1 0 S +0.62 1.54
113 1 58 1 1,2 0 L 20.74 1.67
114 1 61 1 2 1 D S +2.60 6.06
118 1 37 1 2 0 D +1.02 2.03
140 1 61 1 1 0 D +6.91 120.26
141 1 57 1 3 0 D +2.71 6.54
149 1 44 1 1,2 0 D +1.85 3.61
156 1 50 1 1 0 D +1.32 2.50
157 1 56 1 3 0 D +1.45 2.73
202 1 47 1 1 0 L +4.23 18.77
a. Sex 1 = male; 2 = female.
b. Hepatitis b surface antigen (HBsAg) presence in serum: 0 = no, 1 = yes.
c. NT = non-tumor; T = tumor.
d. Intensity of HBxAg staining was evaluated as 0 (no signal) through 3 (intense signal).
e. Tissue distribution of HBxAg: S = scattered, L = lobular, D = diffuse.
f. Negative DDCt value = elevated expression of miR-148a in tumor; positive DDCt value = elevated expression of miR-148a in non-tumor liver.
g. Fold change is calculated as 2
DDCt. The average fold change for elevated miR-148a was calculated by adding up the fold-change from each patient with a positive
DDCt value divided by the number of patients with a positive DDCt value. The positive DDCt values listed in this table are plotted in Figure 1 and represent elevated
miR-148a levels in liver compared to tumor. Parallel calculations were performed to determine the average fold change among patients with negative DDCt values,
which are plotted in Figure 1 as elevated miR-148a levels in tumor compared to liver.
doi:10.1371/journal.pone.0035331.t002
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ylated (inactivated) PTEN (p-PTEN, Ser380/Thr382/383) and
PI3K were determined. The results showed that siURG11
partially suppressed URG11 protein levels (Figure 7A) (P ,
0.01), indicating siURG11 was functional. siURG11 treatment
increased levels of total PTEN (P , 0.02), and depressed the levels
of p-PTEN (P , 0.01). Treatment with siURG11 also resulted in
decreased PI3K levels (Figure 7A) (P , 0.02). Together, these
results suggest URG11 activates PI3K by suppressing PTEN. This
was supported by the results of qRT-PCR, which showed that
siURG11 treatment up-regulated PTEN mRNA 2.1 6 0.14-fold
in HepG2CAT cells, 1.73 6 0.22-fold in HepG2X cells and 3.0 6
0.35-fold in HepG2URG11 cells (data not shown). When these
cultures were treated with PTEN siRNA (siPTEN), URG11
protein and mRNA levels were unchanged (data not shown).
Hence, PTEN does not have any impact upon URG11 expression.
However, siPTEN enhanced Akt and b-catenin expression (data
not shown), as previously published [30].
The finding that URG11 inhibits PTEN raises the possibility
this inhibition may also occur at the PTEN promoter. To test this,
PTEN promoter activity was determined in HepG2CAT,
HepG2X, HepG2URG11 cells. In URG11 over-expressing or
HBx expressing cells, PTEN promoter activity was decreased 28%
compared to HepG2CAT cells (P , 0.05) (Figure 7B). When this
experiment was repeated by transiently transfecting siURG11,
there was a significant increase in PTEN promoter activity in
HepG2X and HepG2URG11 cells compared to parallel cultures
treated with control siRNA (P , 0.01) (Figure 7C). However,
immunoprecipitation (IP) failed to show any binding between
PTEN and URG11 (data not shown). Thus, URG11 may also
inhibit PTEN through suppressing the PTEN promoter.
Discussion
Deregulated expression of miRNAs has been reported in many
human malignancies [31–33]. Functional characterization of these
miRNAs and their target proteins in tumorigenesis has been
important in identifying novel therapeutic targets [31,34–36].
Given the centrality of HBx to HBV associated HCC [4], and that
the HBx target, URG11 strongly stimulates hepatocellular growth
Figure 2. Expression of miR-148a in tumor and non-tumor liver
tissues. Each bar represents data collected from one patient. The
difference in miRNA expression between tumor (T) and non-tumor (NT)
was determined by qRT-PCR and determination of DDCT, where DDCt
= DCt of miR-148a in tumor – DCt of miR-148a in non-tumor. U6 was
used for normalization. Negative values indicate that miR-148a levels
were higher in tumor compared to adjacent non-tumor. Positive values
indicate that miR-148a levels were higher in NT (liver) compared to T.
aHBx NT, HBx T: HBx staining in tumor (T) and nontumor (NT) is scored
as follows: 0 = negative, 1 = up to 25% of cells stained positive, 2 =
25–50% of cells stained positive, 3 = . 50% cells stained positive.
bDx
NT refers to diagnosis of lesions in nontumor liver. These are as follows:
0 = no significant lesions, 1 = chronic hepatitis, 2 = cirrhosis.
cedmon
T refers to the Edmondson classification of cellular differentiation within
tumor nodules. They are as follows: 1 = Edmondson I-II, 2 =
Edmondson II, 3 = Edmondson II-III, 4 = Edmondson III. dVein inv T
refers to venous invasion of the tumor nodule, where 0 = no evidence
for invasion, and 1 = presence of venous invasion. eEncap T refers to
tumor encapsulation, where 0 = none and 1 = encapsulation.
doi:10.1371/journal.pone.0035331.g002
Figure 3. Effect of anti-miR-148a on cell phenotype. HepG2CAT,
HepG2X and HepG2URG11 cells were (A) transiently transfected with
anti-miR-148a or (B) stably transduced with recombinant lentivirus
encoding anti-miR-148a. In both cases, cell growth was evaluated by
MTT assay on days 1, 2 and 3 of culture. All values were normalized to
cells treated only with transfection reagent and are presented as a ratio
of test:control O.D. values. (C) Serum starved cells were analyzed by
flow cytometry on day 3 after the addition of serum. The percentage of
cells in G1,S,G2/M phases are indicated in each panel.
doi:10.1371/journal.pone.0035331.g003
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HepG2X, HepG2URG11 and HepG2CAT cells to identify
differentially expressed miRNAs. The results (Table 1) identified
miR-148a as one of the up-regulated miRNAs in cells expressing
HBx or over-expressing URG11. In 19 T/NT tissue pairs from as
many patients with HBV associated HCC, miR-148a was up-
regulated an average of 14-fold in NT tissue from 13 patients. In
the remaining 6 patients, miR-148a was elevated an average of 5-
fold in T (Table 2, Figure 2). miR-148a stimulated cell viability,
cell migration, anchorage independent cell growth and tumori-
genesis in SCID mice (Table 3, Figure 3–4) and appears to target
the tumor suppressor PTEN (Figure 5). Inactivation of PTEN
resulted in the activation of PI3K/Akt and b-catenin (Figure 6)
and may involve URG11 inhibition of the PTEN promoter
(Figure 7). Thus, HBx up-regulation of URG11 and miR-148a
may be two mechanisms that block PTEN activity, resulting in the
activation of b-catenin signaling (Figure 8). This supports earlier
work showing that HBx stimulated PI3K/Akt and stabilized b-
catenin [37].
URG11 was discovered when HepG2X and HepG2CAT cells
were subjected to subtractive hybridization [17]. The location of
up-regulated URG11 in hepatocytes surrounding tumor nodules,
and that it stimulates cell growth by activating wild type b-catenin,
suggests that this protein promotes early stages of HCC [18]. The
finding herein, that URG11 over-expression is associated with
elevated expression of miR-148a, which then blocks the translation
of PTEN, contributes importantly to understanding the centrality
of URG11 in the activation of PI3K/Akt and b-catenin. The fact
that the tumor suppressor, p53, activates expression of PTEN [38],
and that HBx inactivates p53 and PTEN [27,39–41] provides
another mechanism whereby PTEN inactivation contributes to
HCC. The ability of PTEN to up-regulate p21
WAF1/CIP1/SDI1
[42], and that HBx suppresses p21
WAF1 expression [43], suggest
that the HBx inactivation of PTEN accelerates cell cycle
progression, which was seen herein. Inactivation of PTEN also
correlates with activation of PI3K/Akt, resulting in the up-
regulation of MDM-2, which promotes tumorigenesis [44]. The
fact that PTEN is absent in about 50% of HCC cases [45] suggest
that loss of this tumor suppressor is common. Further, the finding
that HBx constitutively activates oncogene signaling in the liver
may be a mechanism whereby HBV may overcome oncogene
induced senescence [46].
miR-148a was first shown to block apoptosis [47] by
modulating the levels of cytochrome P450 3A4 via post-
transcriptionally regulating the 39UTR of the Pregnane X
Recepter (PXR) mRNA [48]. Since PXR contributes to the
detoxification of xenobiotics in the liver [49–51], the inverse
relationship between miR-148a and PXR in chronic liver disease
(CLD) may promote toxic liver damage. The function of miR-
148a is also likely to be cell type dependent, since it is down-
regulated in acute myeloid leukemia [52,53]. In addition, down-
regulated expression of miR-148a by hypermethylation was
associated with metastasis in many tumor types [54], and with
up-regulation of metastasis associated genes such as subunit 1 of
the general transcription factor IIH [55]. miR-148a was also
shown to repress DNA methyltransferase 1 (DNMT1) and
DNMT3B [56,57]. HBx activates DNMT1, which suppresses
the tumor suppressor, p16
INK4a [58]. Importantly, most HBx and
up-regulated miR-148a were found in the NT compartment of
clinical samples from tumor bearing patients (Figure 2, Table 2),
suggesting that epigenetic changes involving hypermethylation
occur prior to tumor appearance and may promote carcinogen-
esis. In the present work, up-regulated miR-148a in the liver was
associated with the appearance of aggressive tumors (Edmonson
Figure 4. Effect of anti-miR148a on cell migration and
anchorage independent growth. (A) Migration of HepG2CAT,
HepG2X, and HepG2URG11 cells stably expressing anti-miR-148a or
control anti-miR. The top portion of this panel shows the results of
a single experiment, while the graphical representation below is the
average from 3 independent experiments. The black bar in the
photomicrographs is 50um. (B) Summary of soft agar assays for
HepG2CAT, HepG2X and HepG2URG11 cells stably expressing anti-miR-
148a or control anti-miR. The average number of colonies reported here
was from three independent experiments performed in triplicate. * = P
, 0.05; ** = P , 0.01 in the Student’s t test.
doi:10.1371/journal.pone.0035331.g004
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Cell line Treatment average weight of tumors (gms) student’s t test (p-value)
HepG2X anti-miR-Ctrl anti-miR-148a 1.48 6 0.72 0.90 6 0.44 , 0.05
HepG2URG11 anti-miR-Ctrl anti-miR-148a 1.30 6 0.60 0.38 6 0.43 , 0.04
HepG2CAT anti-miR-Ctrl anti-miR-148a 0.40 6 0.33 0.34 6 0.25 . 0.5
doi:10.1371/journal.pone.0035331.t003
Figure 5. Effect of anti-miR-148a on PTEN expression. (A) Homology between the PTEN 39UTR and anti-miR-148a. (B) PTEN protein levels in
cells stably expressing anti-miR-148a or anti-miR control were determined by western blotting. (C) HepG2CAT, HepG2X, HepG2URG11 cells were
transiently co-transfected with anti-miR-148a or anti-miR-Ctrl and a PTEN 39UTR expression plasmid. Firefly (test) and Renilla (control) luciferase
activities were measured after 48hr. The ratios were calculated from the Firefly luciferase: Renilla luciferase readings. * = P , 0.05 and ** = P ,
0.01 in the Student’s t test.
doi:10.1371/journal.pone.0035331.g005
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and by the ability of elevated miR-148a to promote tumorigenesis
(Table 3). However, the fact that up-regulated miR-148a was
found in mostly NT herein, combined with its ability to stimulate
viability, proliferation, migration and growth in soft agar
(Figure 3–4), suggest that tissue remodeling and metastasis are
early events in HBV associated HCC instead of late events
associated with tumor progression. Since CLD involves tissue
regeneration and remodeling, up-regulation of miR-148a in the
chronically infected liver may promote the transition of hepato-
cytes into tumor cells. Once accomplished, miR-148a (and HBx) is
no longer selected for, and their expression levels decrease. Thus,
miR-148a may promote tumorigenesis from the non-tumor
compartment but is no longer active once tumor appears.
PTEN is suppressed by miR-148a in HBV associated HCC
(Figure 5) although other mechanisms may also be operative. For
example, PTEN is down-regulated by miR-214 in ovarian cancer
[59]. In addition, miR-21 which down-regulates PTEN, is up-
regulated in liver and HCC [60], suggesting up-regulated miR-21
is associated with disease progression. The finding of elevated
miR-21 in HepG2X and HepG2URG11 compared to HepG2-
CAT cells, suggests that it may also be a target of HBx. Further,
miR-216a and miR-217, both of which target PTEN, activate Akt
through PTEN down-regulation in kidney disorders [61].
Additional work will be needed to investigate whether miR-148a
targets other proteins in addition to PTEN that are important to
pathogenesis of HBV-mediated HCC. Antagonists of endogenous
miR-148a may be a useful therapeutic strategy for enhancing
PTEN expression and suppressing Akt levels in the HBV infected
liver.
Materials and Methods
Cell Lines
HepG2 and Hep3B cells constitutively expressing CAT, HBx,
or URG11 were constructed in the lab and used as previously
reported [18]. Hep3BCAT, Hep3BX, Hep3BURG11 were
constructed in the same way as previously reported [18]. All were
made by transduction using recombinant retroviruses encoding
CAT, HBx or URG11. Each transduced culture was treated with
G418 (800 ug/ml; GIBCO/BRL, Grand Island, NY) for 14 days
to remove uninfected cells, and each culture propagated without
selection of individual colonies. For the detection of CAT activity,
equivalent amounts of cell lysates were incubated with
14C-
chloramphenicol, and the extent of acetylation analyzed by thin
layer chromatograpy and autoradiography. HBx and URG11
expressing cultures were initially characterized by western blotting
for these recombinant proteins. Cultures were then propagated in
G418 indefinitely. Additional details of these cultures were
previously published [8].
Small RNA Isolation
Small RNAs were isolated from cells and 19 pairs of HCC tissue
samples using the mirVana miRNA isolation kit and PARIS
miRNA isolation kit (both from Ambion, Austin, TX), respective-
ly, by the enclosed protocols. The concentration of small RNA was
determined by O.D. 260/280nm absorbance.
Identification of HBx-related miRNA by Microarray
Analysis
RNA samples from HepG2X and HepG2CAT cells, 50 mg
from each cell line, were sent to LC Sciences (Houston, TX) for
paired miRNA microarray analysis. Differentially expressed HBx-
related miRNAs were identified by Cy3 (HepG2X)/Cy5 (HepG2-
CAT) ratio and P , 0.01. RNA samples from HepG2URG11 and
HepG2CAT cells were analyzed by the same protocol. The results
reported herein represent the average fold change in expression of
each miRNA from three independently performed experiments in
Table 1. Both arrays were compliant to MIAME guidelines and
deposited in GEO with accession number GSE33854.
Patient Tissues
Nineteen pairs of fresh and paraffin-embedded samples, each
containing tumor (HCC) and adjacent non-tumor (liver), were
collected from HCC patients treated at Queen Mary Hospital of
Hong Kong University. These samples had accompanying
documentation for clinical, pathological and laboratory evalua-
tions in Table 2. These samples were de-identified and their use
was approved by the institutional review boards from both Hong
Kong University and Temple University.
Quantification of miRNA Expression in Cells and Tissues
by qRT-PCR
Tissue and cell line miRNA expression was determined by real
time quantitative RT-PCR using Eppendorf’s realplex Mastercy-
cler following the manufacturer’s protocol. Briefly, 25 ng of small
RNA was used for each qRT-PCR reaction. The PCR reaction
mixture was denatured at 95uC for 15 min and then run for 40
cycles (94uC for 15 sec, 55uC for 30 sec, and 70uC for 30 sec).
Melting curve analysis was run at the same time to rule out non-
specific reactions or contamination. U6 was used for normaliza-
tion. Agarose gel electrophoresis, using 2.5% gels, was used for
Figure 6. Effect of anti-miR-148a upon the expression levels of
Akt, GSK3b, and b-catenin. The indicated cell lines were stably
transfected with anti-miR-148a (or control miRNA) and then analyzed
for total and active b-catenin, p-GSK3b, as well as total and p-Akt by
western blotting. The relative amounts of each, normalized to b-actin,
are presented below each blot.
doi:10.1371/journal.pone.0035331.g006
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triplicates. The difference in miRNA expression was determined
by DDCT. mirVana qRT-PCR miRNA Detection Kit, reverse
transcriptase and PCR primer sets (hsa-miR-148a and U6), miR-
negative control 1, and hsa-miR-148a inhibitor (anti-miR-148a)
were all purchased from Ambion.
URG11 Specific Small Interfering RNAs (siURG11) and
Primers
The PTEN siRNA kit was purchased from Cell Signaling
Technology (Danvers, MA). URG11 siRNA sequence and
protocol to transfect cells were described previously [18]. Parallel
wells were transfected with non-targeting siControl #1 siRNA or
with transfection reagent only (DharmaFECT1 from Dharmacon,
Lafayette, CO). The primers designed for URG11 and PTEN
mRNA are: URG11 forward: tgtgccgagactgcaactac; URG11
reverse: gcaatctggacaggaagagc; PTEN forward: cgacgggaaga-
caagttcat; PTEN reverse: gctag cctctggatttgacg; b-actin forward:
aagagctatgagctgccga; b-actin reverse: tacggatgtcaacgtcacac.
Establishment of pmiRZip-148a Stable Expressing Cell
Lines
Three million 293TN cells in a fresh 10-cm plate were plated
and transfected with 10 mg of the pPACK Packaging Plasmid
mixed with 2 mg of pmiRZip-148a or corresponding control
vector using LipofectamineTM (Invitrogen, Carlsbad, CA). Super-
natants were collected at 48 hrs post-transfection, clarified by
centrifugation, mixed with Polybrene, and then used for trans-
duction. After 72 hrs, cells were selected with 100ug/ml
puromycin for 2 weeks, and then the lentivirus infected cultures
enriched by fluorescence activated cell sorting, and propagated
long term. Lentiviral based anti-mir-148a construct (pmiRZip-
Figure 7. The relationship between URG11 and PTEN. (A) URG11, PTEN, p-PTEN and PI3K protein expression in the indicated cultures
transiently transfected with siURG11 or control siRNA. The numbers listed under each blot represent the band intensities after normalization to b-
actin. (B) PTEN promoter activity (indicated by firefly luciferase activity) and phRL_null (the renilla luciferase control) were transiently co-transfected
into the indicated cell lines. Luciferase activities were measured 48 hrs later. (C) PTEN promoter activity was assayed in cells 48 hrs after transient
transfection with siURG11 or control siRNA. Each of the experiments in this figure was repeated at least three times.
doi:10.1371/journal.pone.0035331.g007
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pPACKF1
TM Lentivector Packaging Kit and the 293TN producer
cell line were all purchased from System Biosciences (Mountain
View, CA).
Effects of miRNAs on Cell Growth
Cells were seeded in triplicate on collagen coated 96 well plates
(5,000 cells/well) (Nunc, Rochester, NY) and cultured in complete
medium over night at 37uC and 5% CO2. Cells were then
transiently transfected with 100 ng of anti-miR-148a (Ambion)
using DharmaFECT1. Cell proliferation was determined on days
1, 2 and 3 in the CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega, Madison, WI). miR-negative control
1 was used for normalization.
Anchorage Independent Growth, Tumorigenesis and Cell
Migration Assays
To evaluate anchorage independent growth, single cell suspen-
sions of 1 x 10
4 cells were mixed with 0.4% agar (Sigma, St. Louis,
MO) in complete growth medium and seeded in triplicates into 6-
well plates coated with 0.8% hardened agar. Plates were incubated
at 37uC for 28 days. Colonies $ 1 mm in diameter were counted
under code by light microscopy.
For tumorigenicity studies, two groups of 10 six-week-old SCID
mice (Charles River Laboratories, Wilmington, MA) were injected
subcutaneously at a single site with 6 x 10
6 cells. Tumor onset was
scored visually and by palpitation independently by two trained
lab personnel. Tumor sizes were determined by wet weight at the
time of euthanasia (6 weeks). These experiments were approved by
the Institutional Animal Care and Use Committee at Temple
University.
To evaluate cell migration, single cell suspensions of 1.5610
5
cells were plated in triplicates into 6-well BD BioCoat
TM
Matrigel
TM Invasion Chambers (BD, Franklin Lakes, NJ) accord-
ing to enclosed instructions. Cell migration was observed after 24h
by hematoxylin and eosin (H & E) staining.
PTEN 39UTR Constructs and luCiferase Reporter Assay
The pEZX-PTEN-39UTR construct (Genecopoeia, Rockville,
MD), which contains the PTEN 39UTR sequence, has the
putative binding site for miR-148a downstream of the firefly
luciferase stop codon. It also contains the Renilla luciferase
sequence downstream of the early CMV promoter as an internal
control. Three additional constructs, identical to pEZX-PTEN-
39UTR but each containing unique point mutations in one or both
miR-148a binding sites, were also made (Genecopoeia) and tested.
The sequences of these mutants are listed in Table S1. Cells were
plated (5,000 cells/well) in 96 well plates and co-transfected with
100ng of the pEZX-PTEN-39UTR and 100 ng of anti-miR-148a,
using DharmaFECT1. Luciferase assays were performed after
48 hrs using the Luc-Pair miR Luciferase Assay (Genecopoeia) in
a Glowmax luminometer (Promega, Madison, WI). Firefly
luciferase activity was normalized to renilla luciferase expression
for each sample.
PTEN Promoter Luciferase Assay
The PTEN promoter luciferase plasmid was purchased from
Switchgear Genomics (Menlo Park, CA). The phRL-Null Renilla
luciferase plasmid (Promega) was used as an internal control. Co-
transfection of 100 ng of PTEN promoter luciferase and 10 ng of
phRL-Null was performed with DharmaFECT1. Luciferase
activity was determined by the Promega Steady-Glo Luciferase
Assay Reagent (Promega). To determine whether URG11 inhibits
PTEN promoter activity, URG11 specific siRNA was co-
transfected with 100 ng of PTEN promoter luciferase and 10 ng
of phRL-Null. Parallel wells were transfected with non-targeting
siControl #1 siRNA.
Western Blotting
Sodium dodecyl-sulfate-polyacrylamide gel electrophoresis and
western blotting were carried out as described earlier [18].
Samples containing 30–50 mg of protein were prepared in RIPA
buffer for analysis. Primary antibodies included rabbit anti-
URG11 [17] (1:2000), rabbit anti-PTEN (1:1000), rabbit anti-
phospho-PTEN (Ser380/Thr382/383, 1:1000) rabbit anti-phos-
pho-Akt (Ser 473, 1:1000), rabbit anti-Akt (1:1000), rabbit anti-
GSK3b (Ser9, 1:1000) and rabbit anti-PI3K (D4E2, 1:1000) (all
from Cell Signaling Technology), mouse monoclonal antibody
against activated wild-type b-catenin (clone8E7,1:500, Millipore,
Burlington, MA), and mouse monoclonal b-catenin antibody (E-5,
1:1000, Santa Cruz Biotechnology, Santa Cruz, CA). HRP labeled
second antibodies against mouse (1:5000) and rabbit (1:5000) IgG
were purchased from Sigma Chemical Co. (St. Louis, MO).
Mouse anti-b-actin monoclonal antibody (clone AC-15, Sigma,
1:10,000) was used as an internal control for normalization. All
signals were detected by Amersham ECL PlexTM (Piscataway,
NJ).
Statistics
Differences in miRNA expression between tumor and non-
tumor were arbitrary determined by DDCT. The Student’s t test
was used to analyze cell growth. The relationships between HBx,
miR-148a, and histopathology were assessed by 262 Chi-square
Figure 8. Model of miR148a associated signaling pathway.
miR148a increases b-catenin expression by inhibiting PTEN. See the text
for additional details.
doi:10.1371/journal.pone.0035331.g008
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when P , 0.05. * = P , 0.05. ** = P , 0.01.
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